Press Releases July 23, 2014

July 7, 2014
ISA Pharmaceuticals Appoints Ronald Loggers as Chief Executive Officer
munotherapy company focusing on rationally designed immunotherapeutics against cancer and persistent viral infections, today announced that the Company has hired Ronald Loggers, the former Chairman of ISA´s Supervisory Board, as Chief Executive Officer. More

July 1, 2014
Stage 3 Phase 2 Study of DARPin Abicipar Pegol (previously MP0112) Supports Progressing to Phase III
Stage 3 Phase 2 Study of DARPin Abicipar Pegol (previously MP0112) Supports Progressing to Phase III Development Program. More

June 27, 2014
InDex Pharmaceuticals announces results from COLLECT, a clinical trial of Kappaproct
InDex Pharmaceuticals announces results from COLLECT, a clinical trial of Kappaproct in the treatment of moderate to severe Ulcerative Colitis. More

June 26, 2014
Serial Entrepreneur Dr. Peter Hirth Joins Nuevolution as Corporate Advisor
Nuevolution is very pleased to announce that Dr. Peter Hirth has joined Nuevolution as a Corporate Advisor. More

June 24, 2014
New financing round: crealytics receives mid single-digit million amount for further inter...
New financing round: crealytics receives mid single-digit million amount for further international expansion and development of its semantic PPC technology “camato”. More

June 24, 2014
EyeTechCare appoints Dietrich Wolf as chief executive officer
The new CEO intends to pursue market development in Europe and beyond. More

June 23, 2014
Portfolio company Diurnal reports positive Phase 2 results
IP Group plc (LSE: IPO) (“IP Group” or “the Company” or “the Group”), the developer of intellectual property based businesses, is pleased to note that portfolio company Diurnal Limited ('Diurnal”) has today announced positive results from a 6-month Phase 2 clinical study in 16 adults suffering from the rare disease Congenital Adrenal Hyperplasia (“CAH”). More

June 23, 2014
ProBioGen Signs GlymaxX ADCC Enhancement Technology License Deal
ProBioGen AG announced today that it has signed a non-exclusive commercial multi-product licensing agreement with Novartis on its GlymaxX Antibody Glyco-Engineering technology. More

June 23, 2014
GP Bullhound advises MyOptique Group Ltd on Series C investment round
GP Bullhound, the technology investment bank, is pleased to have acted as exclusive financial advisor to MyOptique Group Ltd on an investment round led by Beringea, Korys, Cipio Partners and Silicon Valley Bank. More